CHICAGO, ILLINOIS--(CCNMatthews - Nov. 14, 2006) - Resverlogix Corp. (“Resverlogix”) (TSX:RVX), is pleased to announce that the Company has conducted its first Clinical Advisory meeting in Chicago, prior to the American Heart Association’s Scientific meetings. Resverlogix’s lead candidate RVX208 has repeatedly shown the pronounced potency to increase plasma ApoA-I levels in animal models. ApoA-I is a validated key target for cardiovascular disease (CVD) protection. After a thorough review of Resverlogix science the expert panel has recommended that Resverlogix constitute a clinical advisory board for its ApoA-I enhancing lead program NexVasTM PR.
